NEW DELHI : India’s largest drug-maker Sun Pharmaceutical Industries Ltd departed from its usual practice of providing a sales guidance for 2020-21, saying that it expects near-term uncertainty due to the covid-19 pandemic. “As for the guidance, I wish we could give you a guidance.
However, given the uncertainties in near term we are breaking from our normal practice of giving a guidance. We will revisit this stance in the next quarter," Sun Pharma managing director Dilip Shanghvi said in an investor conference call.
Last year, the company had given a guidance of consolidated sales growth being in the low to mid-teens. Eventually the drug-maker’s sales were up 13% for 2019-20.